CORDIS - EU research results
CORDIS

A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Project description

Innovative screening for cancer detection in urine samples

According to the World Health Organisation, 50 % of cancer deaths could be avoided with successful early detection. Current standard detection procedures are often invasive and risky, specific for a limited number of cancer types and very expensive. The market is currently lacking a general test, suitable for the whole population, for detecting any type of cancer before the presentation of symptoms. The EU-funded Cancersensing project aims to overcome this problem by developing a highly accurate and rapid screening platform for the early detection of multiple types of cancer from a single urine sample. The platform will include a specific and sensitive test that measures cancer-related biomarkers present in the urine, in combination with a diagnostic software suite. The current feasibility assessment phase of the project will establish market strategy, a supply chain and a further development plan.

Objective

Globally, more than 18 million people are diagnosed with cancer each year and this number is set to exceed 22 million by 2030. According to the World Health Organization (WHO), about 50% of cancer deaths could be avoided by enabling early cancer detection. Unfortunately, the market is still lacking a general test, suitable for the whole population, for detecting any type of cancer before the presentation of symptoms. Current gold standard procedures are highly invasive and risky, specific for one cancer type, and highly expensive. These factors limit their adoption to suspected cancer cases – i.e. after the presentation of symptoms, delaying cancer diagnosis and contributing to the huge economic burden on healthcare systems.

To overcome this problem, MDB DIAGNOSIS GROUP LTD (‘MDBD’) has developed Cancersensing, a revolutionary accurate and rapid screening platform for early diagnosis of multiple cancers from a single urine sample. The platform includes a highly specific and sensitive test that measures cancer-related biomarkers present in the urine, and a diagnostic software suite powered by proprietary machine learning algorithms and reference databases. Cancersensing makes cancer detection in its early stage available to all, maximizing survival rates and quality of life for patients, and reducing treatment costs and the cancer-related economic and societal burden.

During the feasibility assessment, MDBD will establish a go-to-market strategy and a supply chain, and define further development plan. During the second phase of innovation project, MDBD will optimize the Cancersensing screening platform, and perform clinical validation activities with hospital partners in the EU to obtain regulatory approval for commercialization.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

MDB DIAGNOSIS GROUP LIMITED
Net EU contribution
€ 50 000,00
Address
BUILDING 6 30 FRIERN PARK
N12 9DA LONDON
United Kingdom

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
London Outer London — West and North West Barnet
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00